Arrowstreet Capital
ALNY icon

Arrowstreet Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Arrowstreet Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Buy
+49,601
New +$15M 0.01% 953
2026
Q1 		– Sell
-1,127,162
Closed -$448M – 1824
2025
Q4 		$448M Sell
1,127,162
-228,447
-17% -$101M 0.26% 86
2025
Q3 		$618M Buy
1,355,609
+1,185,909
+699% +$483M 0.39% 57
2025
Q2 		$55.3M Buy
169,700
+165,645
+4,085% +$45.8M 0.04% 395
2025
Q1 		$1.09M Buy
+4,055
New +$1.04M ﹤0.01% 1455
2024
Q3 		– Sell
-14,971
Closed -$3.64M – 1721
2024
Q2 		$3.64M Buy
+14,971
New +$2.36M ﹤0.01% 930
2021
Q1 		– Sell
-61,300
Closed -$7.97M – 2214
2020
Q4 		$7.97M Buy
61,300
+57,583
+1,549% +$7.69M 0.01% 980
2020
Q3 		$541K Buy
3,717
+1,517
+69% +$216K ﹤0.01% 1996
2020
Q2 		$326K Buy
+2,200
New +$297K ﹤0.01% 2084
2020
Q1 		– Sell
-3,300
Closed -$380K – 1844
2019
Q4 		$380K Buy
+3,300
New +$329K ﹤0.01% 1534
2017
Q4 		– Sell
-51,485
Closed -$6.05M – 1227
2017
Q3 		$6.05M Buy
+51,485
New +$4.39M 0.02% 468
2015
Q3 		– Sell
-13,274
Closed -$1.59M – 1333
2015
Q2 		$1.59M Buy
+13,274
New +$1.59M 0.01% 694
2014
Q2 		– Sell
-43,081
Closed -$2.89M – 955
2014
Q1 		$2.89M Buy
+43,081
New +$3.34M 0.02% 568

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's ALNY Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 49,601 shares worth $14.9M. The stake represents 0.01% of the portfolio and ranks #953 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in ALNY as recently as Q4 2025.

Arrowstreet Capital first reported a position in ALNY in Q1 2014 and has held it in 13 quarters since. The position peaked at $618M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Arrowstreet Capital held 49,601 shares of Alnylam Pharmaceuticals worth $14.9M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Arrowstreet Capital position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #953 holding.
  • Arrowstreet Capital first reported a position in Alnylam Pharmaceuticals in Q1 2014 and has held it in 13 quarters since.
  • Arrowstreet Capital's Alnylam Pharmaceuticals position peaked at $618M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.